Research, page-1293

I have wondered this too. But AF hasn't prominently mentioned this with any focus so have not really expected much in this regard. It's a case of expect nothing and be pleasantly surprised if it gets launched suddenly - in our favour is that it tends to be easier to get approval and launch in the EU than it is USA (noting the EU wouldn't want to be at a disadvantage when it comes to lung tech).

Interesting that your screenshot shows a launch flagged for some time in FY23. Can I ask what date this document was from? Is it the latest on Europe.

I suspect this will be another case of an out of the blue (positive) announcement that they've got approval (after working quietly in the background and not making any solid promises) - like in the case of getting TGA approval earlier than anticipated, winning the govt grant to build the XV scanner, and I-MED among others. Hope so anyways.

Europe is a very large market when compared to Aus so would light a rocket under the share price in multiples.

I'm surprised they aren't looking at NZ or Canada yet? Or are they and we just don't know